Paradigm Biocapital Advisors LP Has $60.79 Million Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA)

Paradigm Biocapital Advisors LP lifted its stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 31.0% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,437,339 shares of the company's stock after acquiring an additional 340,488 shares during the quarter. Vera Therapeutics comprises approximately 2.1% of Paradigm Biocapital Advisors LP's holdings, making the stock its 14th largest position. Paradigm Biocapital Advisors LP owned about 2.27% of Vera Therapeutics worth $60,785,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. SG Americas Securities LLC boosted its stake in Vera Therapeutics by 116.7% during the 4th quarter. SG Americas Securities LLC now owns 20,270 shares of the company's stock valued at $857,000 after purchasing an additional 10,916 shares during the period. Barclays PLC boosted its stake in Vera Therapeutics by 94.1% during the 3rd quarter. Barclays PLC now owns 85,395 shares of the company's stock valued at $3,774,000 after purchasing an additional 41,394 shares during the period. Raymond James Financial Inc. bought a new stake in Vera Therapeutics during the 4th quarter valued at approximately $2,948,000. Victory Capital Management Inc. boosted its stake in Vera Therapeutics by 515.0% during the 4th quarter. Victory Capital Management Inc. now owns 235,267 shares of the company's stock valued at $9,949,000 after purchasing an additional 197,014 shares during the period. Finally, Teacher Retirement System of Texas boosted its stake in Vera Therapeutics by 44.2% during the 4th quarter. Teacher Retirement System of Texas now owns 12,860 shares of the company's stock valued at $544,000 after purchasing an additional 3,942 shares during the period. Institutional investors own 99.21% of the company's stock.

Vera Therapeutics Stock Performance

Vera Therapeutics stock traded down $0.08 during trading hours on Friday, hitting $21.25. The stock had a trading volume of 955,320 shares, compared to its average volume of 780,251. The company has a 50-day moving average of $23.49 and a two-hundred day moving average of $34.01. The company has a quick ratio of 13.76, a current ratio of 13.76 and a debt-to-equity ratio of 0.17. The company has a market cap of $1.35 billion, a PE ratio of -8.14 and a beta of 1.28. Vera Therapeutics, Inc. has a fifty-two week low of $18.53 and a fifty-two week high of $51.61.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.06). During the same quarter in the previous year, the business earned ($0.56) earnings per share. On average, equities research analysts anticipate that Vera Therapeutics, Inc. will post -2.89 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts recently weighed in on VERA shares. Cantor Fitzgerald decreased their target price on Vera Therapeutics from $107.00 to $100.00 and set an "overweight" rating for the company in a research note on Wednesday, May 7th. Wolfe Research started coverage on Vera Therapeutics in a research note on Tuesday, February 4th. They set an "outperform" rating and a $49.00 target price for the company. HC Wainwright started coverage on Vera Therapeutics in a research note on Monday, May 5th. They set a "buy" rating and a $75.00 target price for the company. The Goldman Sachs Group started coverage on Vera Therapeutics in a research note on Tuesday, January 28th. They set a "buy" rating and a $58.00 target price for the company. Finally, Guggenheim increased their target price on Vera Therapeutics from $59.00 to $61.00 and gave the company a "buy" rating in a research note on Thursday, February 27th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, Vera Therapeutics has a consensus rating of "Buy" and a consensus price target of $63.33.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.